Overview

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Status:
Withdrawn

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if Itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB/Stage IV or recurrent whose tumors have EGFR activating mutations.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Erlotinib Hydrochloride
Mitogens